Results 41 to 50 of about 28,679 (139)

Vaccines’ New Era-RNA Vaccine

Viruses, 2023
RNA vaccines, including conventional messenger RNA (mRNA) vaccines, circular RNA (circRNA) vaccines, and self-amplifying RNA (saRNA) vaccines, have ushered in a promising future and revolutionized vaccine development.
Wenshuo Zhou, Linglei Jiang, Shimiao Liao, Feifei Wu, Guohuan Yang, Li Hou, Lan Liu, Xinping Pan, William Jia, Yuntao Zhang   +9 more
doaj   +1 more source

Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis

Nature Communications, 2020
Antimicrobial peptide LL37 can bind nucleic acids and potentiate their sensing by endosomal TLRs. Here the authors show that LL37 binds to RNA from neutrophil extracellular traps (NETs), which amplifies inflammation and production of more LL37 and NETs ...
Franziska Herster, Zsofia Bittner, Nathan K. Archer, Sabine Dickhöfer, David Eisel, Tatjana Eigenbrod, Thomas Knorpp, Nicole Schneiderhan-Marra, Markus W. Löffler, Hubert Kalbacher, Tim Vierbuchen, Holger Heine, Lloyd S. Miller, Dominik Hartl, Lukas Freund, Knut Schäkel, Martin Heister, Kamran Ghoreschi, Alexander N. R. Weber   +18 more
doaj   +1 more source

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

Vaccines, 2022
The seasonal flu vaccine is, essentially, the only known way to prevent influenza epidemics. However, this approach has limited efficacy due to the high diversity of influenza viruses. Several techniques could potentially overcome this obstacle. A recent
Andrei A. Deviatkin, Ruslan A. Simonov, Kseniya A. Trutneva, Anna A. Maznina, Elena M. Khavina, Pavel Y. Volchkov   +5 more
doaj   +1 more source

The Limitless Future of RNA Therapeutics

Frontiers in Bioengineering and Biotechnology, 2021
Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications.
Tulsi Ram Damase, Roman Sukhovershin, Christian Boada, Francesca Taraballi, Francesca Taraballi, Roderic I. Pettigrew, John P. Cooke   +6 more
doaj   +1 more source

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines.

PLoS Pathogens, 2022
The optimal vaccination strategy to boost responses in the context of pre-existing immune memory to the SARS-CoV-2 spike (S) glycoprotein is an important question for global public health.
Tamara Elliott, Hannah M Cheeseman, Abbey B Evans, Suzanne Day, Leon R McFarlane, Jessica O'Hara, Mohini Kalyan, Fahimah Amini, Tom Cole, Alan Winston, Sarah Fidler, Katrina M Pollock, James A Harker, Robin J Shattock   +13 more
doaj   +1 more source

Research progress on the quality control of mRNA vaccines

Expert Review of Vaccines
Introduction The mRNA vaccine technologies have progressed rapidly in recent years. The COVID-19 pandemic has accelerated the application of mRNA vaccines, with research and development and clinical trials underway for many vaccines.
Chaoying Hu, Yu Bai, Jianyang Liu, Yiping Wang, Qian He, Xuanxuan Zhang, Feiran Cheng, Miao Xu, Qunying Mao, Zhenglun Liang   +9 more
doaj   +1 more source

Delivery of self-amplifying RNA vaccines in in vitro reconstituted virus-like particles.

PLoS ONE, 2019
Many mRNA-based vaccines have been investigated for their specific potential to activate dendritic cells (DCs), the highly-specialized antigen-presenting cells of the immune system that play a key role in inducing effective CD4+ and CD8+ T-cell responses.
Adam Biddlecome, Habtom H Habte, Katherine M McGrath, Sharmila Sambanthamoorthy, Melanie Wurm, Martina M Sykora, Charles M Knobler, Ivo C Lorenz, Marcio Lasaro, Knut Elbers, William M Gelbart   +10 more
doaj   +1 more source

Self-amplifying RNA vaccine development: transcriptomic profiling of a Venezuelan equine encephalitis virus self-amplifying RNA vector in human muscle

, 2022
Next-generation RNA constructs are emerging as exciting new platforms for both vaccination and therapeutic applications. The last few years have seen the first mRNA vaccines licensed for use in humans and the first-in-human clinical trial of a self-amplifying RNA vaccine.
openaire   +2 more sources

A Novel Self‐Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations

Advanced Science
The efficacy and safety of self‐amplifying mRNA (saRNA) have been demonstrated in COVID‐19 vaccine applications. Unlike conventional non‐replicating mRNA (nrmRNA), saRNA offers a key advantage: its self‐replication mechanism fosters efficient expression ...
Yue Gong, Danni Yong, Gensheng Liu, Jiang Xu, Jun Ding, William Jia   +5 more
doaj   +1 more source

Optimization of the production and function of self-amplifying RNA vaccines

, 2022
Recently, RNA-based vaccines have become highly attractive, with proven ability to induce protective immunes responses against COVID-19, matched with their rapid and relatively simple production. Self-amplifying RNA (saRNA) may provide additional advantages due to its ability to: i) self-replicate facilitating exponential antigen expression; ii) induce
openaire   +2 more sources